» Articles » PMID: 4246140

Australia Antigen (a Hepatitis-associated Antigen): Purification and Physical Properties

Overview
Journal J Exp Med
Date 1970 Jun 1
PMID 4246140
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Australia antigen [Au(1)], a particle associated with viral hepatitis, was isolated from the plasma of a patient with chronic anicteric hepatitis and leukemia who had received radioactive phosphorus. We have found that the immunoreactivity and appearance of Au(1) in the electron microscope were not altered by treatment with enzymes including trypsin, pronase, lipase, phospholipase C, ribonuclease, deoxyribonuclease, amylase, and neuraminidase. In contrast, other serum constituents were degraded by these enzymes. Therefore, treatment of the patient's plasma with many enzymes was exploited as an initial step for the isolation of Au(1). Subsequently, Au(1) was purified from the enzyme-treated (32)P-labeled plasma by gel filtration through Sephadex G-200 and centrifugation through sucrose and in cesium chloride gradients. There were no detectable human serum components in the purest fractions, as tested by immunoelectrophoresis and immunodiffusion. The density of the purified Au(1) was 1.21 in CsCl. The particle measured about 200 A in diameter, was predominantly spherical in shape and appeared to be composed of subunits. Nucleic acids were not detected by spectrophotometric, radiochemical, and chemical analyses. Immunoreactivity of purified Au(1) was destroyed by heating for 1 hr at 85 degrees C but was stable at 56 degrees C. Treatment with Carnoy's solution (3 parts ethanol:1 part glacial acetic acid) followed by pronase disrupted the particles as seen with the electron microscope. These findings, combined with other published information on Australia antigen and viral hepatitis, suggest that the bulk of Australia antigen in the blood of this patient is an incomplete virus or virus capsid.

Citing Articles

Past, present, and future of long-term treatment for hepatitis B virus.

Broquetas T, Carrion J World J Gastroenterol. 2023; 29(25):3964-3983.

PMID: 37476586 PMC: 10354584. DOI: 10.3748/wjg.v29.i25.3964.


Virus-like Particles as Preventive and Therapeutic Cancer Vaccines.

Tornesello A, Tagliamonte M, Buonaguro F, Tornesello M, Buonaguro L Vaccines (Basel). 2022; 10(2).

PMID: 35214685 PMC: 8879290. DOI: 10.3390/vaccines10020227.


The chimpanzee model for hepatitis B virus infection.

Wieland S Cold Spring Harb Perspect Med. 2015; 5(6).

PMID: 26033082 PMC: 4448699. DOI: 10.1101/cshperspect.a021469.


Animal models and the molecular biology of hepadnavirus infection.

Mason W Cold Spring Harb Perspect Med. 2015; 5(4).

PMID: 25833941 PMC: 4382722. DOI: 10.1101/cshperspect.a021352.


Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives.

Gerlich W Med Microbiol Immunol. 2014; 204(1):39-55.

PMID: 25523195 DOI: 10.1007/s00430-014-0373-y.


References
1.
Alter H, Blumberg B . Further studies on a "new" human isoprecipitin system (Australia antigen). Blood. 1966; 27(3):297-309. View

2.
Blumberg B, Gerstley B, HUNGERFORD D, London W, Sutnick A . A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med. 1967; 66(5):924-31. DOI: 10.7326/0003-4819-66-5-924. View

3.
Bayer M, Blumberg B, Werner B . Particles associated with Australia antigen in the sera of patients with leukaemia, Down's Syndrome and hepatitis. Nature. 1968; 218(5146):1057-9. DOI: 10.1038/2181057a0. View

4.
Prince A . Relation of Australia and SH antigens. Lancet. 1968; 2(7565):462-3. DOI: 10.1016/s0140-6736(68)90512-6. View

5.
Sutnick A, London W, Gerstley B, Cronlund M, Blumberg B . Anicteric hepatitis associated with Australia antigen. Occurrence in patients with Down's syndrome. JAMA. 1968; 205(10):670-4. View